Background. Sexually transmitted infections (STIs), including human immunodeficiency virus (HIV), disproportionately affect adolescents and young adults (AYAs) ages 13-24 years. Sexually transmitted infections likewise are a risk factor for HIV acquisition and transmission; however, there is a lack of data on STI acquisition in HIV-infected AYAs.
Half of the 20 million new sexually transmitted infections (STIs) and one fourth of all new human immunodeficiency virus (HIV) infections in the United States occur in adolescents and young adults (AYAs) between 13 and 24 years of age [1, 2] . According to the 2015 Youth Risk Behavior Survey, 41% of American teens have had sex at least once, 11.5% have had 4 or more sexual partners, and 30% were currently sexually active, with only 57% reporting condom use during their most recent intercourse [3] . In 2013, the National College Health Assessment showed that consistent condom use among sexually active college students was low, with only 3.1%, 26.2%, and 9.7% of participants who had oral, vaginal, and anal intercourse, respectively, reporting condom use every time they engaged in sexual activity [4] .
This pattern of high-risk behavior is similar in HIV-infected AYAs [5, 6] , who have the added risk of secondary HIV transmission. Tassiopoulos et al [7] demonstrated that 62% of perinatally HIV-infected sexually active youth reported unprotected sexual intercourse. Of these, half had HIV-1 ribonucleic acid viral loads (VLs) ≥5000 copies/mL and 75% had drug-resistant virus. Highrisk sexual behavior is also well documented in non-perinatally HIV-infected youth [8] . Underlying HIV infection not only may increase the severity of a newly acquired STIs, but concomitant STIs increase the risk of secondary HIV transmission [9] .
Administration of effective antiretroviral therapy (ART) with associated virologic suppression benefits the HIV-infected individual and reduces secondary HIV transmission [10] . There are conflicting results regarding the impact of ART and virologic suppression on the acquisition of other STIs. Brownstein et al [11] recently reported that subjects from an Atlanta-based cohort who had uncontrolled HIV infection had 2.8 (95% confidence interval [CI], 1.2-6.9) times higher odds of having at least 1 STI relative to those with controlled infection. Likewise, Mullins et al [5] showed that young women infected with HIV who were not receiving ART were more likely to acquire trichomonas than HIV-infected women on ART. However, other studies have failed to demonstrate an association between treatment status and STI acquisition [12, 13] . Discrepancies between studies may be related to methodological as well as diagnostic differences where poor sensitivity of certain diagnostic methods could have underestimated the true incidence of STIs. This is the first multicenter study in the United States to determine the incidence of STIs among HIV-infected AYAs in the human papillomavirus (HPV) vaccine era. We also evaluated the impact of demographic and HIV infection characteristics and HIV control on risk of STIs among HIV-infected AYAs.
METHODS

Participants
The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1074 was a multicenter, prospective observational cohort study of HIV-infected children and adolescents that assessed long-term adverse outcomes of HIV infection and complications of ART. Enrollment started in April 2009 and ended in June 2013, with continued follow-up through June 2014. Data for this analysis were retrieved on April 15, 2014. A total of 1201 HIV-infected infants, children, and adolescents at 39 US IMPAACT sites who had participated in the Pediatric AIDS Clinical Trial Group 219/219C long-term follow-up study or in IMPAACT interventional studies selected for coenrollment were enrolled. This analysis focused on AYAs between 12.5 and <25 years of age. Participants who had not reached 12.5 years by the end of follow-up and those who were 26 years or older at the first chart review (which abstracted data from 1 year before entry) were excluded from the analysis. Institutional review boards of all study sites approved this study, and informed consent/assent was obtained from all participants or guardians.
Data Collection
Entry and subsequent annual medical record abstractions were performed. Data from the previous year, including demographic information, clinically significant diagnoses, ART, CD4 count, and VL, were recorded. Antiretroviral therapy regimens were classified as highly active ART (HAART) (at least 3 drugs from at least 2 classes), non-HAART ART, or no ART at initial chart abstraction and at time of STI event. CD4 count, VL, and event data available for participants on coenrolled IMPAACT studies were also included in the analysis database.
Definitions
Sexually Transmitted Infections
Clinical diagnoses were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 17.0 [14] [15] [16] . The MedDRA-preferred terms were categorized into 8 STI groups: HPV, chlamydia, gonorrhea, syphilis, trichomonas, herpes, chancroid, or indeterminate (cervicitis, epididymitis, pelvic inflammatory disease) (Appendix 1). Sexually transmitted infections were included if they occurred at age 12.5 years or older.
The incidence rate of STIs, overall, was based on the first occurrence of any STI during the study period among those without any historical STI events. Participants with any STI reported before the beginning of the study period (and after age 12.5 years) were considered to have an historical STI and were excluded from computation of the overall STI incidence rate. However, participants with an STI of 1 type (eg, HPV infection) before the study period were included in the computation of incidence rates of other specific STI types (eg, chlamydia infection) not reported before the study period. Incidence rates of specific STIs were based on the first occurrence of that specific STI during the study period among those without that type of STI historically. To evaluate STI recurrence, a subsequent episode of the same STI in an individual subject was considered if the onset date followed the resolution date of the previous episode. If no resolution date was recorded for the preceding episode, that episode was assumed to have resolved 3 months after its onset date. An event reported on multiple dates but without a resolution or subsequent new event onset date was considered a single ongoing episode. Human papillomavirus-derived conditions (eg, cervical dysplasia/warts) and herpes simplex virus (HSV) infections were considered chronic, and therefore only a single event was recorded.
Well Controlled Human Immunodeficiency Virus
Human immunodeficiency virus control was defined as mean VL <500 copies/mL and CD4 count >500 cells/mm 3 in the 1-year period before the onset date of an STI. For VLs recorded as less than a lower limit of quantitation, the value of the lower limit of quantitation was used in calculations of mean VL. Subjects not meeting both the VL and CD4 criteria were considered to have poor HIV control. For participants with events occurring within the year before study entry and participants enrolled in P1074 less than 1 year before STI onset, available VL and CD4 count values within 1 year before STI onset were used.
For subjects without STIs, a standardized interval defined as the median time from the adjusted study start date (the later of the year before study entry or the 12.5th birthday) to first incident STI among subjects with STIs was added to the adjusted study start date to derive an "index date. " If later than the 25th birthday, the index date was censored at the 25th birthday. Human immunodeficiency virus control was determined based on VL and CD4 count values during the year preceding the index date for subjects without STIs.
Statistical Methods
Demographic and HIV disease characteristics were summarized using descriptive statistics, comparing youth with and without STIs during the study period. The χ 2 tests were used to compare the 2 groups for categorical variables, and Wilcoxon rank-sum tests were used for continuous measures. The incidence rate per 100 person-years and 95% exact CIs were computed for occurrence of any STI and for each of the 8 specific STI categories, overall and by sex and mode of HIV transmission.
Univariate and multivariable logistic regression models were used to compare HIV control and other potential risk factors among subjects with and without STIs during the study period. Adjustment for time on study between 12.5 and 25 years was also included, because follow-up time within this age range varied. Risk factors with P < .15 in the univariate model were included in multivariable models. Two sets of models were created, 1 including the indicator for HIV control as defined above and a second one exploring the separate but simultaneous effects of CD4 count and VL (>500 cells/ mm 3 and <500 copies/mL, respectively) and adjusting for other model covariates. Additional analyses explored associations between risk factors and HPV and chlamydia infections. Sensitivity analyses were performed using CD4 count and VL thresholds of >200 cells/mm 3 and <500 copies/mL, respectively. The primary logistic regression analysis was also repeated with stratification by sex and mode of HIV transmission. Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, North Carolina), and statistical significance was assessed at P < .05.
RESULTS
A total of 1042 participants met the age-related criteria for analysis; 49% were male, 61% were black, and the mean age at first chart review was 18.3 years (standard deviation = 3.8 years). Most participants (88%) acquired HIV perinatally, and 8.4% (88 participants) had a history of STI more than 1 year before entry. One hundred twenty participants had at least 1 reported STI during the study period; however, 27 of those participants also had an STI reported before the study period and were excluded from calculation of the overall STI incidence rate. The remaining 93 participants with incident STIs yielded an overall STI incidence rate of 2.8/100 person-years (95% CI, 2.26-3.44) ( Table 1 ). When evaluating individual STI categories, of the 120 subjects that had an STI during the study period, 112 had a new category-specific STI: 82 subjects had 1, 20 had 2, 7 had 3, and 3 had 4 category-specific incident-events, yielding a total of 155 new category-specific events. Human papillomavirus and chlamydial infections were the most common STIs reported, with incidence rates of 1.66 (95% CI, 1.26-2.15) and 0.86 (95% CI, 0.58-1.22) per 100 person-years, respectively. Females and non-perinatally infected participants generally had higher incidence rates than their respective counterparts (Table 1) .
Subjects with or without an STI during the study period did not differ in race/ethnicity, time on study, or mortality, but differed by sex, age, route of HIV acquisition, history of STI before the study period (historical STI), CD4 count, VL, and ART (Table 2) . Univariate analysis showed a significantly higher risk of having an STI among AYAs who were older, female, non-perinatally HIV-infected, not on ART, who had a historical STI, and had poor HIV control (Table 3 ). In the multivariable analysis, risk of an STI continued to be associated with older age, female sex, non-perinatally acquired HIV infection, and poor HIV 3 ) and VL <500 copies/mL, similar results were obtained.
Human Papillomavirus and Chlamydia Infections
Similar to the cumulative STI analysis, HPV infection risk was associated in the multivariable model with older age, female sex, poor HIV control, and non-perinatal HIV acquisition. However, chlamydia infection was only associated with female sex, non-perinatal HIV acquisition, and years on study (Table 4) . When virologic control and immunologic status were examined separately in multivariable models adjusting for other risk factors, HPV infection was associated with poorer immunologic status (aOR = 2.37; 95% CI, 1.24-4.54) but less so with lack of virologic suppression (aOR = 1.85; 95% CI, 0.96-3.54); chlamydia infections were not significantly associated with either parameter (immunologic status: aOR = 0.99, 95% CI, 0.41-2.34; virologic suppression aOR = 1.52, 95% CI, 0.64-3.62) (Appendix 3). Using the modified definition of HIV control (CD4 >200/ mm 3 , VL <500 copies/mL), HPV infection remained associated with poor HIV control (aOR = 2.54; 95% CI, 1.41-4.60), whereas chlamydia infection was not (aOR = 1.45; 95% CI, 0.68-3.12).
Sexually Transmitted Infections by Sex and Mode of Human Immunodeficiency Virus Transmission
Among perinatally HIV-infected AYAs, STI acquisition was associated with the same risk factors as for the overall population (older age, female, poor HIV control), whereas no significant risk factors were identified among the smaller non-perinatally infected subgroup. Risk factors differed by sex, with older age (aOR = 1.13; 95% CI, 1.04-1.23) and poor HIV control (aOR = 2.24; 95% CI, 1.27-3.96) significant risk factors for females, whereas only non-perinatal HIV acquisition (aOR = 7.34; 95% CI, 2.83-19.04) was associated with STI occurrence in males.
Recurrent Sexually Transmitted Infections
Of the 120 participants with an STI during the study period, 79 had an STI on only 1 occasion, 25 had an STI on 2 occasions, and 16 had STIs on 3 or more occasions. Chlamydia and trichomonas infections were the most common STIs among participants with more than 1 episode. person-years in HIV-infected vs uninfected males, respectively. Chlamydia was the most common STI, followed by gonorrhea [5] . In a mixed perinatally and non-perinatally HIV-infected Number of participants with complete data that were included in the logistical regression model. Lack of HIV control is defined as either mean CD4 count <500 cells or mean VL copies >500 within the 1 year prior to event or index date. Number of participants with complete data that were included in the logistical regression model. Lack of HIV control is defined as either mean CD4 count <500 cells or mean VL copies >500 within the 1 year before event or index date.
cohort of 13-to 24-year-old AYAs in Atlanta, an incidence rate of 35 STIs per 100 person-years was documented, with syphilis and chlamydia most commonly reported, followed by HPV infections [11] . In the present study, incidence rates stratified by mode of HIV transmission indicated that rates of STIs in non-perinatally infected individuals were higher than in perinatally infected participants (11.0 vs 2.3 per 100 person-years) and of the same order of magnitude as rates observed in the REACH and Atlanta cohorts that consisted predominantly of non-perinatally HIV-infected subjects (100% and 66%, respectively). Among HIV-infected adults, the Sun Study reported that 7% of participants had an incident STI within 6 months of enrollment in HIV care, with rectal chlamydia and oropharyngeal gonorrhea diagnosed most often [17] . Although comparisons among studies are limited by differences in study populations, these accumulated results indicate that many HIV-infected adolescents and adults engage in high-risk sexual behaviors resulting in STI acquisition and, possibly, secondary HIV transmission, reinforcing the need for routine screening and prevention counseling for STIs [18] .
Risk factors for STI acquisition in our cohort included older age, female sex, non-perinatal HIV acquisition, and uncontrolled HIV infection. The association with older age has previously been described in HIV-infected and HIV-uninfected AYAs and may relate to increasing sexual activity [7, 19, 20] . Greater STI detection in females may reflect increased screening, higher rates of symptom development, and less power to negotiate condom use compared with males [2, 5, [21] [22] [23] . In addition, adolescent women may have increased susceptibility to STIs due to a higher degree of cervical ectopy; this biologic feature coupled with impaired cell-mediated immunity from HIV infection may increase the risk of STI acquisition and persistence of certain infections such as HPV [24] .
Uncontrolled HIV was a significant risk factor for STI acquisition. However, we are unable to determine whether HIV control biologically affects STI acquisition or whether poor HIV control is a surrogate marker for increased risk behavior and STI exposure (or both), because socio-behavioral data were not collected. It is interesting to note that the association of immunologic status with STI risk outweighed the influence of poor virologic suppression. In addition, in independent HPV and chlamydia models, the risk of HPV, but not chlamydia infection, was significantly associated with poor HIV control, and, again, in particular with low CD4 count. Responses to chronic infections such as HPV and HSV may require a competent immune system to control persistence and prevent reactivation. Studies in HIV-infected and uninfected women have shown a decreased incidence of oncogenic HPV types in patients with higher CD4 + , validating our results and suggesting a higher clearance rate of HPV serotypes as the CD4 + increases [25] [26] [27] . Alternatively, our study may have lacked statistical power to establish such an association for chlamydia coinfection. Human papillomavirus was the most common STI identified, consistent with data for the general US population [28] . Despite a clear relationship of HPV infection with the development of multiple cancers [29] [30] [31] [32] and the availability of an efficacious and safe vaccine, uptake of HPV vaccination has been suboptimal, with only 21% of males and 35% of females between 13-17 years of age receiving this vaccine [33] [34] [35] . A 50%-100% lifetime risk of HPV acquisition in sexually active, unvaccinated males and females has been estimated [36] , with HIV-infected individuals tending to have worse outcomes than HIV-uninfected individuals [37] [38] [39] and poor HIV control potentially increasing the risk of HPV-related malignancies. Demonstration of HPV as the most common STI in this multicenter cohort highlights the importance of vaccinating HIVinfected adolescents before sexual debut [40] .
There are several limitations to this study. Underreporting of the true incidence of STIs could have occurred because STI screening practices likely varied among IMPAACT sites, subjects may not have disclosed STI diagnoses made at other clinical care sites, and there may have been inconsistency among sites in reporting STI diagnoses to the study database. These limitations may have led to underestimation of incidence rates and potentially confounded the association between poor HIV control and STI acquisition. Because this study was a secondary analysis, covariates and outcomes were limited to those available in the dataset; this precluded evaluating clinic-based interventions (educational and psychological) as well as socio-behavioral parameters as potential risk factors for STI acquisition. Because the database lacked information regarding sexual debut, some subjects included in the analysis may have not been sexually active and would have been inappropriately assigned to the at-risk population. Finally, the terms used to identify HPV infection included different variations of dysplasia, rather than specific HPV testing; the lack of such testing may have led to overestimation of the association between uncontrolled HIV and HPV infection.
CONCLUSIONS
In summary, AYAs with HIV infection had substantial STI rates that are concerning both for the morbidity associated with STIs and also for the increased risk of secondary HIV transmission. Risk factors for STIs included older age, female sex, non-perinatal HIV acquisition, and poor HIV control. Human papillomavirus infection was the most common STI, emphasizing the need for timely HPV vaccination in addition to behavioral interventions to reduce overall STI risk.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious Diseases Society online.
